Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

lerability of BL-7040 in patients with moderately active ulcerative colitis. Twenty-two patients were enrolled in the multi-center, proof-of-concept clinical trial, and 16 patients completed the study (five weeks of treatment plus two weeks of follow-up). During the five-week treatment period, patients received 12mg/day for up to three weeks, followed by 40mg/day for two additional weeks.

Statistical analyses were performed on the 16 patients completing five weeks of treatment, and the primary endpoint of clinical response was assessed by the Mayo score reduction between the last days of treatment compared to baseline. Fifty percent of patients met the primary endpoint, while the remaining patients demonstrated a stable clinical condition or minor improvement. Fifty-six percent of patients recorded a decrease in rectal bleeding of at least 1 point and 69% had a rectal-bleeding sub-score of ≤1 (and in six of these 11 patients no rectal bleeding was seen at all). Fifty percent of patients completing study treatment also met the secondary endpoint assessed by the partial Mayo score, while all other patients were clinically stable or demonstrated some improvement. Furthermore, 50% demonstrated mucosal healing evaluated by endoscopy sub-score measurements.

The drug was highly safe and well tolerated by the study participants, with very low incidence of drug related mild-moderate adverse events (AE) and one serious AE not related to BL-7040 treatment. Patients were very satisfied from the safety and tolerability profile of the treatment and emphasized the ease of oral administration.

About BL-7040         
BL-7040 is an orally available, synthetic oligonucleotide with a unique dual activity, being developed for the treatment of inflammatory bowel disease (IBD). It has a specific agonist effect on a receptor involved in the immune system and inflammatory reactions called Toll-Like Receptor 9 (TLR
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014 Luoxis Diagnostics, Inc., ... AMPE), today announced the presentation of three clinical ... as a broadly applicable and robust research tool ... body in response to injury, illness, or stress.  ... collaboration with Luoxis, academic and pharmaceutical research partners, ...
(Date:11/24/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... today that Sergio Traversa , chief executive officer, ... Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014.  ... Bel Air Hotel, which is located at 11461 Sunset ... The presentation is scheduled for 8:30 a.m. ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2
(Date:11/26/2014)... November 26, 2014 Increasing demand ... include image guided surgeries has paved way for ... Rising incidence of various types of cancers and ... increase in demand for these owing to their ... contrast media injectors market can also be attributed ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules ... mesothelioma that looks and acts similar to asbestos-induced mesothelioma. ... the research. Click here to read it now. ... and Experimental Medicine in Hannover injected 500 lab rats ... rats eventually developed mesothelioma , how quickly it ...
(Date:11/26/2014)... For its December issue , ... Report on Blue Cross and Blue Shield Plans* interviewed ... varied strategies the two Blues plans are implementing in ... for sleep apnea, ranging from brick-and-mortar retail stores to ... to increased rates of a variety of serious disorders, ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 With Thousand ... of dollars, the prosthodontists at the Anacapa Dental Art Institute ... dental procedures can be daunting for some. , That is ... the procedures they offer. , “No dentist wants cost to ... set of teeth,” said Dr. Mamaly Reshad, partner in the ...
(Date:11/26/2014)... the video interviewing specialist, has today announced the appointment ... Officer, in addition to the formal opening of it’s ... appointed as Chief Operating Officer. He is joined by ... Officer. , Mr Jones is a seasoned tech, media ... with The Walt Disney Company and Adventis where he ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2
... uncovers "biologic treatments", ROSEMONT, Ill., Nov. 3 ... proteins repair fractured bones published in the,November 2008 ... of Orthopaedic,Surgeons ( http://www.jaaos.org/ ) demonstrates that understanding ... improved and less invasive,treatments for fractures., "The ...
... Nov. 3 World Champion athlete and health,and ... as a member of the,California Governor,s Council on ... to the student body of NEW Academy Canoga ... healthy lifestyles., (Photo: http://www.newscom.com/cgi-bin/prnh/20081103/AQM074 ), ...
... Pa., Nov. 3 BMP Sunstone,Corporation (Nasdaq: BJGP ... plans to release third quarter 2008 financial results on,Monday, ... Company will hold a conference call at 9:00 am ... third quarter 2008 results.,Listeners may access the call by ...
... Provider Services Cited as Pivotal to ... Billing Efficiency Statewide, NASHVILLE, Tenn., Nov. 3 ... solutions for the healthcare industry,has been named the electronic ... Hospital Association (MHA). Emdeon was selected,through a competitive bidding ...
... $50 million in annual revenue for SXC,s ... 3 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or ... announces that its,pharmacy benefit management (PBM) division, informedRx, ... of San Mateo (HPSM) valued at more,than $50 ...
... seatbelts more common for adolescents illegally at the wheel, study ... if the thought of teenagers driving before they,ve gotten their ... kids are also more likely to drive while drinking or ... they get behind the wheel. , Reporting in the November ...
Cached Medicine News:Health News:The Biology of Broken Bones Leads to New Treatments 2Health News:The Biology of Broken Bones Leads to New Treatments 3Health News:Laila Ali Debuts as Member of California Governor's Council on Physical Fitness and Sports 2Health News:BMP Sunstone to Report Third Quarter 2008 Financial Results 2Health News:Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange 2Health News:SXC Health Solutions announces PBM services agreement with Health Plan of San Mateo 2Health News:Many Unlicensed Teen Drivers Put Safety Last 2Health News:Many Unlicensed Teen Drivers Put Safety Last 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: